The BCR-ABL1 gene fusion is susceptible to drug targeting by tyrosine kinase inhibitors (TKIs), which are the standard of care for patients with CML in all phases, although patients are typically diagnosed in the chronic phase (ie, CML-CP).2 Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.